AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
BioNTech:HC Wainwright Downgrades to Buy, PT Reduced to $136 from $138
ByAinvest
Thursday, Aug 14, 2025 11:53 am ET1min read
BioNTech:HC Wainwright Downgrades to Buy, PT Reduced to $136 from $138
Victoria, Australia, July 2, 2025 — BioNTech SE, a leading biotechnology company, has seen its stock rating downgraded by HC Wainwright from a "buy" to a "buy" with a reduced price target of $136, down from $138 [1]. The downgrade comes amidst significant developments in the company's clinical trial platform and recent financial performance.The downgrade follows BioNTech's partnership with the Peter MacCallum Cancer Centre to establish a clinical trial platform in Victoria, aimed at improving access to investigational cancer treatments [1]. The platform, which includes key delivery partners like Austin Health, Alfred Health, and Monash Health, is designed to streamline clinical trials and expedite the development of innovative therapies.
Despite the downgrade, BioNTech reported strong quarterly revenue of $306.46 million, exceeding analyst expectations, but it also reported a loss of ($1.60) EPS, falling short of the anticipated ($1.41) [2]. This indicates ongoing volatility in the company's earnings performance.
The downgrade by HC Wainwright comes amidst a mixed picture of institutional investor sentiment. TD Asset Management Inc significantly reduced its stake in BioNTech by 74%, but several other institutional investors increased their holdings, with increases ranging from 7.1% to 34.2% [2]. The company's stock has seen a 241,226 shares traded on Friday, reaching $112.09, with a market cap of $26.95 billion and a PE ratio of -70.11 [2].
Analysts have a mixed sentiment towards BioNTech, with five analysts rating the stock with a hold rating and thirteen giving a buy rating, resulting in an average rating of "Moderate Buy" and an average price target of $135.91 [2].
References:
[1] https://www.invest.vic.gov.au/news-and-events/news/2025/august/new-biontech-clinical-trail-platform-to-improve-clinical-trial-access-for-cancer-patients
[2] https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-trims-stake-in-biontech-se-sponsored-adr-nasdaqbntx-2025-08-05/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet